The Qinetiq share price tanks on earnings. Is now the time to buy?

After its latest trading update, the Qinetiq share price took quite a tumble, but is this a buying opportunity? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week wasn’t particularly pleasant for the Qinetiq (LSE:QQ) share price. Shareholders of this UK defence business watched the stock collapse by double-digits last Thursday after management released a trading update. Some of this negative performance did reverse the following day. And its 12-month return is still around 13%. But the question remains, what spooked investors? And is this decline actually a buying opportunity for my portfolio? Let’s take a closer look.

The Qinetiq share price tumbles on trading update

In the words of management, the company has achieved “strong underlying operating performance” and “continued strategic momentum”. Looking at the initial numbers, I’m inclined to agree. Defence order intake reached £700m, roughly 25% higher than the first half of its 2021 fiscal year (from April 2020 to April 2021). This is largely thanks to securing new contracts with the US Army, the Australian Department of Defence, and the UK Ministry of Defence. As a result, revenue growth is estimated to be around 5% for its 2022 fiscal year.

Five percent hardly sound particularly exciting. But given that the defence industry average revenue growth rate is around 3.2%, that’s not bad, in my opinion. So why did the Qinetiq share price fall?

Should you invest £1,000 in Unilever right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Unilever made the list?

See the 6 stocks

Despite the firm’s efforts to emphasise its progress, it seems investors were less than pleased to hear that supply chain disruptions are creating problems. The company is trying to find a quick solution. But it has warned that the situation may create a one-time £15m expense. Comparing that with last year’s operating income of £119m shows a potential 13% decline in underlying earnings. And to add fuel to the fire, the mission shift out of Afghanistan has resulted in operating profit margins coming in at the lower end of previously issued guidance, placing the margin around 11%.

Needless to say, that’s not good news. So, seeing such a sharp decline in the Qinetiq share price is hardly surprising.

Taking a step back

As frustrating as the situation is, supply chain disruptions are ultimately a short-term problem. And the adverse effects could be easily reversed in the future. How? Qinetiq’s US operations have been something of a disruptive force. And management is actively pursuing its goal of doubling the size of this division over the next five years through a mixture of both organic and acquisitive growth.

Meanwhile, the firm’s ability to continue securing new contracts worldwide serves as supporting evidence that demand isn’t going away. And with an estimated $20bn addressable market size, the long-term growth opportunities for Qinetiq and its share price seem plentiful. At least, that’s what I think.

The bottom line

All things considered, if I were a shareholder, I wouldn’t be too concerned about this trading update. However, is this a buying opportunity for me? Well, I’m not so sure. It’s hard to make an informed decision about the future of the Qinetiq share price without more data. And CEO Steve Wadey wasn’t particularly generous with details on the earnings call.

The company is planning to release its interim results on 11 November. So for now, I’m going to keep this business on my watchlist until I know more.

Should you invest £1,000 in Unilever right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Unilever made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Why has Warren Buffett built a $318bn war chest?

Mark Hartley looks at legendary investor Warren Buffett's massive stockpile of cash, how investors can learn from his approach and…

Read more »

A pastel colored growing graph with rising rocket.
Dividend Shares

This FTSE 250 share looks ripe for a rebound!

This FTSE 250 share has seen its price slump by 25% in 11 months. However, this stock looks under-priced to…

Read more »

Investing Articles

£10,000 invested in HSBC shares 1 year ago is now worth…

HSBC shares have recently reversed their positive trajectory. Dr James Fox takes a closer look at what's been happening and…

Read more »

Investing Articles

A strong dividend share I’ve bought to target a huge second income!

Looking for the best dividend stocks to buy? Here's one I expect to pay a large second income despite an…

Read more »

Investing Articles

Investors’ confidence is sinking! What should they do as stock markets plummet?

Stock markets are in freefall as trade wars worsen and investor sentiment sinks. What course of action should we all…

Read more »

Investing Articles

How much would an investor need in a Stocks and Shares ISA to earn a £750 monthly passive income?

Mark Hartley whips up a recipe to illustrate how a Stocks and Shares ISA portfolio could eventually generate a solid…

Read more »

Bronze bull and bear figurines
Investing Articles

How much lower can the Nvidia stock price fall?

After the Nasdaq sell-off, where next for the Nvidia stock price? Predicting a recovery or a further fall might be…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£10,000 invested in BAE Systems shares 2 years ago is now worth…

BAE Systems shares have gone from strength to strength, but are they worthy of this elevated valuation. Dr James Fox…

Read more »